Scrip's Round Table at the 2009 Scrip Awards - Personalised Medicine
Personalised medicines are often held up as the holy grail of the pharmaceutical industry. For sure, increasingly sophisticated diagnostic tests are allowing companies to better distinguish between responder/non-responder patient groups.
The pharma industry has witnessed some players making strategic moves into the diagnostics area, driven by advances in science, cost pressure and demands from global medicines regulators.
The panellists debated the likely impact of companies moving from retrospective to prospective trials. They also spoke about the lack of infrastructure at the FDA and the EMA needed to assess increasingly complex diagnostic tests.
While few companies will want to bring wholesale diagnostics capabilities in-house, the panel agreed that the convergence between the therapeutics and diagnostics sectors, and various social monitoring systems, is likely to gather pace.
Scrip Outlook for 2010
|M&A and strategies |
In a year that saw the return of the mega-merger, the Round Table discusses its impact on the industry.
The Round Table
Moderator: Ashley Yeo, Informa Analyst. Scrip 100's Editor: Pete Chan. Videographer: Adam Charlton. Digital artwork: Dale Perkins.